Universal Biosensors Inc (ASX: UBI) Share Price and News

Mr. Coleman is an experienced investment and funds management executive. His career of 30 years has spanned banking and finance, corporate advisory and funds management. Craig is currently the Executive Chairman of Viburnam Funds, an Australian-based investment manager founded in 2007 with investments in private and public equities. During his executive career, Mr. Coleman has held a number of senior executive positions with ANZ Banking Group Ltd, including Managing Director Banking Products, Managing Director Wealth Management, Non-Executive Director E*TRADE Australia Ltd and Head of Retail Banking New Zealand. Mr. Coleman currently retains non-executive directorship position with publicly listed entity Bell Financial Group Limited and is Chairman of Pacific Star Network Limited.

--

Ms. Smith is experienced investment and funds management executive. During her career, Ms. Smith has worked in a number of investment management roles in the funds management industry, where she has been responsible for evaluating and investing in listed and unlisted companies. Ms. Smith was formerly the Head of Private Equity at IFM Investors, a global fund manager, and Chair of the IFM Risk Committee. Ms. Smith was also a member of the IFM Investments Committee, a role she has retained following her retirement from the firm. Prior to her role at IFM, Ms. Smith held investment management roles including more than a decade at National Mutual Funds Management Ltd (NMFM). At NMFM, she managed Australian equity research and strategy, as well as Australian equity portfolios. Ms. Smith is a member of the Audit Committee of the Australian Renewable Energy Authority. She is a trustee director of industry superannuation fund, LUCRF and the Chairperson of the LUCRF Investment Committee. She is a member of the advisory committee for the SA Venture Capital Fund - an SA Government initiative to have a VC fund focused on SA opportunities. She is also a board member of Scale Investors Ltd., a not-for-profit organisation promoting women entrepreneurs and women angel investors in early stage companies.

Mr. Hoey has experience relevant to our Company, with more than 25 years' experience in technology financing and commercialization. Mr. Hoey is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development. Mr. Hoey has served as a non-executive director since March 2016 and has served as a director of Universal Biosensors LLC since August 2021. He has served as a director of Universal Biosensors B.V. since September 2021. Mr. Hoey is currently Chief Executive Office and a director of Vaxxas, Inc., a company which has developed and is commercializing a novel vaccine delivery technology - The NanopatchTM. He also serves as an advisor to Healthcare Ventures LLC. During his career Mr. Hoey has worked in management and leadership roles in the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey served as vice president of business development at PathoGenetix, Inc., a company pioneering single molecular detection technologies for biodefence, clinical, and industrial applications.

Mr. McLean has more than 20 years' business and corporate governance experience and is an experienced senior executive leader with service in the medical technology industry in Australia, Asia and US, most recently with Stryker Corporation (Stryker) as President Asia Pacific from 2017 to 2020. Whilst at Stryker, Mr. McLean led a transformation of Asia Pacific to renew growth in Japan and China and led an accelerated growth strategy for Australia/New Zealand. Prior to his time with Stryker, Mr. McLean was Lion Nathan's Finance Director International/Business Development from 2003 to 2005 and Director Group Risk Assurance & Audit from 2001 to 2003. Since 2021, Mr. McLean has served as an Independent Director and Chairman of the Audit and Risk Committee at Suicide Prevention Australia. Since 2021, Mr. McLean has been an Advisor to Bain & Company. He has also previously served on industry boards in Australia (Medical Technology Association of Australia), Japan (American Medical Devices & Diagnostics Manufacturers Association) and Asia Pacific where he was Vice Chairman of the Asia Pacific Medical Technology Association. Mr. McLean was appointed as an independent director of UBI in March 2022 and has been a member of the Audit and Compliance Committee and the Product and Projects Committee since his appointment to the Board.

-

-